GlassScriptPhysician profile
Jessica L Hansen
NPI 1336651918
$5,764.32
in general payments reported to CMS, 2019-2025
12 companies · $3,789 in 2025
The $3,789 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $253 · 2023: $604 · 2024: $1,012 · 2025: $3,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,525 · Food and Beverage: $2,011 · Travel and Lodging: $839 · Education: $30.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,525.00 |
| Food and Beverage | $2,010.50 |
| Travel and Lodging | $839.43 |
| Education | $30.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $3,612.56 | 2024-2025 | Crysvita |
| Biomarin Pharmaceutical INC. | $716.95 | 2021-2025 | Palynziq, Voxzogo 1.2mg |
| Alexion Pharmaceuticals, INC. | $571.30 | 2022-2024 | Koselugo, Strensiq |
| Genzyme Corporation | $232.43 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $193.28 | 2022-2025 | Dojolvi |
| Horizon Therapeutics Plc | $125.00 | 2023 | Ravicti |
| Amicus Therapeutics, INC. | $102.08 | 2021-2025 | Opfolda, Pombiliti, Galafold |
| Solventum Corporation | $73.56 | 2024 | Prevena Restor Arthroform, Prevena Restor Axioform, V.A.C.Ulta |
| Ptc Therapeutics, INC. | $48.11 | 2025 | |
| Recordati_rare_diseases_inc. | $34.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.22 | 2023 | Elaprase |
| Intrabio INC | $24.39 | 2025 | Aqneursa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.